Overview

A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies

Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
0
Participant gender:
All
Summary
This is a follow-up study with no treatment and only samples being collected.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Criteria
Inclusion Criteria:

- Main Selection Criteria: A subject that has received either ABT-072 or placebo in a prior
study involving ABT-072.

Exclusion Criteria:

- The investigator considers the subject unsuitable for the study for any reasons inclusive
of, but not limited to, failure to comply with study procedures in a prior ABT-072 clinical
study.